Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects

This study has been terminated.
(Interim review indicated that the dose selected was too high for diabetics)
Sponsor:
Information provided by (Responsible Party):
Evolva SA
ClinicalTrials.gov Identifier:
NCT01551381
First received: March 8, 2012
Last updated: June 14, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2012
  Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)